23andMe Holding Co. Class A Common Stock (ME) News
Filter ME News Items
ME News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ME News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ME News From Around the Web
Below are the latest news stories about 23ANDME HOLDING CO that investors may wish to consider to help them evaluate ME as an investment opportunity.
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their careSUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today announced the launch of Discover23®, a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through a Trusted Research Environment ( |
3 Promising US Penny Stocks With Over $9M Market CapAs the U.S. stock market looks to recover from a recent losing streak, with major indices like the Dow Jones and Nasdaq showing signs of strength, investors are exploring diverse opportunities across various sectors. Penny stocks, though sometimes overlooked due to their historical connotations, remain a viable investment option when backed by strong financials. In this article, we explore three penny stocks that exhibit financial robustness and potential for growth, offering investors a... |
What’s next for 23andMe?Amid its plummeting stock value, layoffs and cuts to its drug R&D program, the battered company is carrying on. |
US Penny Stocks: 3 Picks With Market Caps Under $200MAs the S&P 500 and Nasdaq Composite reach record highs, driven by a surge in technology stocks, investors are increasingly exploring diverse opportunities across the market spectrum. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials. |
Do Redditors Think That 23andMe Holding Co. (ME) Has a Big Upside Potential?We recently compiled a list of the 11 Reddit Stocks with Biggest Upside Potential. In this article, we are going to take a look at where 23andMe Holding Co. (NASDAQ:ME) stands against the other Redditor-approved stocks. Paul Hickey, Bespoke co-founder, together with Dana D’Auria, Envestnet co-chief Investment Officer, joined CNBC’s ‘Closing Bell: Overtime’ on November 12 […] |
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & InflammationSUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will leverage a targeted set of aggregated, de-identified genetic an |
23andMe to lay off more than 200 employees amid business strugglesThe genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.” |
23andMe Holding Co (ME) Q2 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...Despite a revenue decline, 23andMe Holding Co (ME) focuses on cost-saving measures and recurring revenue growth to enhance financial stability. |
Q2 2024 23andMe Holding Co. Earnings CallQ2 2024 23andMe Holding Co. Earnings Call |
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic ProgramsOn Thursday, genetics-led consumer healthcare company 23andMe Holding Co. (NASDAQ:ME) announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing the further development of all its therapeutic programs while evaluating strategic alternatives for its clinical and preclinical assets. Also Read: Legal Battle Brews Over 23andMe’s Customer Data Breach Settlement And Arbitration Claimants The company is reducing its overall headcount by over 200 |